Company News
-
August 21, 2024
Extremely promising clinical trial results for the high-sensitivity Point-of-Care (POC) cardiac troponin I test of our partner SpinChip Diagnostics
SpinChip Diagnostics, in which bioMérieux has held an approximate 20% stake since March 2024, has just published results showing the very good performance of its high-sensitivity Point-of-Care (POC) cardiac troponin I (hs-cTnI) assay. This innovative assay, the first of its kind, could significantly improve the diagnosis of acute myocardial infarction. -
July 26, 2024
Paris 2024: National teams choose bioMérieux’s BIOFIRE® PCR solutions to test athletes
During this summer's Olympic and Paralympic Games in Paris, several committees and national teams, including the Dutch delegation, will be using the BIOFIRE® range of PCR test solutions developed by bioMérieux to detect respiratory and gastrointestinal infections in their athletes. -
July 02, 2024
USDA Awards bioMérieux GENE-UP® Pathogenic E. coli (PEC) as Method of Choice for Shiga Toxin-Producing E. coli (STEC) Detection in USDA Food Safety and Inspection Service (USDA-FSIS) Laboratories
GENE-UP® PEC assay is a real-time PCR-based AOAC validated solution for the meat, produce, and food safety industry.
-
June 10, 2024
USDA Awards bioMérieux GENE-UP® CAMPYLOBACTER as Method of Choice for Campylobacter Detection in USDA Food Safety and Inspection Service Laboratories
GENE-UP® CAMPYLOBACTER is a real-time PCR-based solution that delivers results in under an hour and is AOAC validated for a variety of enrichment medias.
-
June 06, 2024
bioMérieux and AnaBioTec Announce Partnership to Support the Implementation of Rapid Mycoplasma Testing
In May 2024, bioMérieux entered into a strategic partnership with AnaBioTec, an analytical service provider for pharmaceutical, biopharmaceutical and cell-based drugs, from early to late phases of development. Both companies intend to advance and transform Mycoplasma testing for the biopharmaceutical and Cell & Gene Therapy (CGT) industries, in Europe.